Researchers at Moffitt Cancer Center have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of ...

Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study The following represents disclosure ...

Infusion product characteristics to predict response to tumor-infiltrating lymphocyte (TIL) therapy in metastatic melanoma (MM). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.

Ochsner MD Anderson Cancer Center at The Gayle and Tom Benson Cancer Center in New Orleans announces a milestone in advanced ...

Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE ...

Please provide your email address to receive an email when new articles are posted on . The addition of pembrolizumab to TIL therapy improved response rates among individuals with metastatic ...

Scientists from the Moffitt Cancer Center say they now have a better understanding why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. It’s not common for cancer surgeons to turn their focus ...

In a new study, TILs significantly predicted both distant disease-free survival and overall survival in early ERBB2-positive breast cancer. TIL levels ≥20% were associated with better outcomes when ...

A new study shows that TIL therapy, a personalized immunotherapy using a patient's own immune cells, significantly improves ...

Richmond, Va.-based VCU Health’s Massey Comprehensive Cancer Center has become the first facility in Virginia to offer tumor-infiltrating lymphocyte therapy for advanced stage melanoma patients. TIL ...

OU Health Stephenson Cancer Center told News 9 on Sunday that it is the only site in Oklahoma that offers a new cell therapy to treat advanced melanoma.